Stocks and Investing
by (remove) : Salim Syed
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Salim Syed
RSSJSONXMLCSV
Fri, August 16, 2024
Tue, August 6, 2024
Tue, June 25, 2024
Thu, May 9, 2024
Tue, March 12, 2024
Tue, March 5, 2024
Thu, February 22, 2024
Thu, November 9, 2023
Mon, August 28, 2023
Mon, August 14, 2023
Wed, May 24, 2023
Mon, May 8, 2023
Fri, April 14, 2023
Tue, March 28, 2023
Tue, February 7, 2023
Wed, November 16, 2022
Tue, November 1, 2022
Wed, September 28, 2022
Wed, August 24, 2022
Tue, August 16, 2022
Tue, May 10, 2022
Wed, January 12, 2022
Mon, November 22, 2021
Wed, November 10, 2021
Tue, October 26, 2021
Mon, August 2, 2021

Salim Syed Upgraded (ATRA) to Buy and Decreased Target to $18 on, Aug 16th, 2024


Published on 2024-10-28 13:43:09 - WOPRAI, Salim Syed
  Print publication without navigation


Salim Syed of Mizuho, Upgraded "Atara Biotherapeutics, Inc." (ATRA) to Buy and Decreased Target from $25 to $18 on, Aug 16th, 2024.

Salim has made no other calls on ATRA in the last 4 months.



There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Robert Burns of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, May 22nd, 2024


These are the ratings of the 2 analyists that currently disagree with Salim


  • John Newman of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $13 on, Tuesday, August 13th, 2024
  • Tommie Reerink of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $11 on, Wednesday, July 17th, 2024
Contributing Sources